300147 *ST香雪制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)54.365-400.870-57.629-18.384-20.184
总资产报酬率 ROA (%)-4.013-19.548-10.882-4.597-5.295
投入资产回报率 ROIC (%)-23.909-58.057-20.929-7.820-8.881

边际利润分析
销售毛利率 (%)32.38027.32524.36534.34824.869
营业利润率 (%)-17.537-57.828-42.209-14.470-21.222
息税前利润/营业总收入 (%)-14.785-66.455-32.876-6.414-13.687
净利润/营业总收入 (%)-35.814-85.921-46.336-17.473-23.074

收益指标分析
经营活动净收益/利润总额(%)51.43028.09148.46139.38575.918
价值变动净收益/利润总额(%)0.6630.1210.63712.318-9.244
营业外收支净额/利润总额(%)48.01530.9866.83414.4589.323

偿债能力分析
流动比率 (X)0.2360.2600.2980.3530.324
速动比率 (X)0.1930.2120.2340.2740.234
资产负债率 (%)103.56699.34880.81172.06568.526
带息债务/全部投入资本 (%)155.645120.68566.82953.75551.032
股东权益/带息债务 (%)-42.279-23.08445.06876.14986.170
股东权益/负债合计 (%)-9.125-5.37717.40932.25438.953
利息保障倍数 (X)-0.780-3.833-2.645-0.611-1.409

营运能力分析
应收账款周转天数 (天)203.129176.068146.725102.156139.642
存货周转天数 (天)111.77098.78996.314104.740134.579